Sirona Biochem Announces Results in Key Study for Biological Inducer

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 14, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB) (the "Company"), a biotechnology company, announced today it has completed a pivotal proof of concept study of its biological inducer for recombinant protein manufacturing.

In the study, Sirona Biochem's inducer produced more protein compared to a leading commercially available inducer at the same concentration. In addition, Sirona Biochem's compound induced synthesis of a soluble recombinant protein in Escherichia coli for up to 24 hours.

"We believe we are on track to producing an inducer that is more stable, can be stored at room temperature and can improve protein yields for recombinant protein manufacturers, which could be particularly useful in producing insulin," said Sean Cunliffe, Chief Business Officer of Sirona Biochem. "The results of this study further validates our proprietary chemistry platform and its potential in improving upon existing carbohydrate molecules," Mr. Cunliffe added.

Inducers are carbohydrates which trigger recombinant protein production. The quality of the inducer is key to the production process and can affect the quality and yield of the protein. Current inducers, because they are carbohydrates, are metabolically unstable, and require special handling conditions.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.